/PRNewswire/ Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease,.
UCB Provides Update on U.S. FDA Review of the Biologics License Application for Bimekizumab Brussels (Belgium), 26th June 2023 - 18:30 CEST - Regulated Information - Inside Information - UCB, a global biopharmaceutical comp.
TORRANCE, Calif., May 15, 2023 /PRNewswire/ Emmaus Life Sciences, Inc. , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on. | May 15, 2023
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia - read this article along with other careers information, tips and advice on BioSpace